Retina

Joshua Mali, MD, discusses the three major risk factors for developing age-related macular degeneration (AMD).

Investigators examine long-term effects of therapeutics in infants.

Ian C. Han, MD, dives into the basics of age-related macular degeneration (AMD) and what patients need to know.

Daniel H. Chang, MD, shares data on a recent study involving a new violet light-filtering chromophore in a preclinical computer simulation testing and randomized clinical study.

Ian C. Han, MD, assistant professor in the Department of Ophthalmology and Visual Sciences, Institute for Vision Research, University of Iowa Hospital and Clinics, dives into the basics of age-related macular degeneration (AMD) and what patients need to know.

Fellows, residents from around the world show promise for future of retinal research.

With NASA’s sights set on Mars, continued research into further understanding and mitigating spaceflight-associated neuro-ocular syndrome is of the utmost importance for astronaut health and space exploration.

Investigators at the Wilmer Eye Institute at the Johns Hopkins University School of Medicine conducting experiments in mouse tissues and human cells found that they may be able improve the success rate for regrowing nerve cells damaged by blinding diseases.

Community involvement, research continue to boost treatment in pediatric population.

Rishi P. Singh, MD, highlights various treatment options available for the management of patients with age-related macular degeneration, as well as the status of potential therapies.

Results of a study analysing cytokine levels in the aqueous humour and serum of patients with nonproliferative diabetic retinopathy with and without diabetic macular oedema support further research investigating transforming growth factor-β-induced Gene Human Clone 30 (BIGH3) as a potential biomarker for DMO.

Emerging technology may facilitate individualized care, disease management.

The FDA has granted Fast Track designation to MeiraGTx's AAV-CNGA3 gene therapy product candidate for the treatment of achromatopsia (ACHM).

Study found that YAG laser vitreolysis was less invasive than pars plana vitrectomy for patients with vitreous opacities.

Higher levels of 3 macular pigments minimize risk of age-related disease.

Study evaluates the impact of surgical procedure on visual outcomes in patients.

BIGH3 is an extracellular matrix protein that can act in an autocrine, paracrine manner.

Diabetes mellitus, which is a common chronic disease in children, can lead to significant eye morbidities with long-lasting effects, including diabetic retinopathy. Treatment should be tailored to the individual patient.

Delivery into the suprachoroidal space may potentially extend the duration of therapeutic action and reduce or relieve the treatment burden for wet AMD.

Amydis announced the successful completion of a pre-investigational new drug (IND) meeting with the FDA for its candidate AMDX-2011P, a small-molecule retinal tracer that targets amyloid beta to diagnosis amyloid angiopathy.

Two teams of researchers from Gyroscope Therapeutics and the University of Pennsylvania are joining forces to explore gene therapy targets for three specific serious eye diseases.

Study results could provide a new preferred treatment paradigm for this population.

Faricimab is the focus of the YOSEMITE and RHINE studies, which investigators say show that the investigational bispecific antibody has the potential to offer lasting vision improvements for patients with diabetic macular oedema.

Prospective randomised trial demonstrates clinical equivalence of biosimilar and reference ranibizumab

Nine pediatric patients with Leber congenital amaurosis show visual improvement in clinical trials.